FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055794120> ?p ?o ?g. }

• W2055794120 endingPage "488" @default.
• W2055794120 startingPage "480" @default.
• W2055794120 abstract "OBJECTIVE To analyze the costs of nitrofurantoin use compared to those of other antibiotics recommended for treatment of uncomplicated urinary tract infection (UTI). PATIENTS AND METHODS We used a decision analysis model to perform cost-minimization and sensitivity analyses to determine the level of trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinolone resistance that would favor the use of nitrofurantoin as a first-line empirical treatment of uncomplicated UTIs. The model used a program perspective to evaluate costs. RESULTS Nitrofurantoin was cost-minimizing when the prevalence of fluoroquinolone resistance exceeded 12% among uropathogens or the prevalence of TMP-SMX resistance exceeded 17%. On 2-way sensitivity analysis, variables that had a significant impact on our cost-minimization threshold included cost of antibiotics and probability of clinical cure with antibiotics. CONCLUSION From a payer perspective, nitrofurantoin appears to be a reasonable alternative to TMP-SMX and fluoroquinolones for empirical treatment of uncomplicated UTIs, especially given the current prevalence of antibiotic resistance among community uropathogens. On the basis of efficacy, cost, and low impact on promoting antimicrobial resistance, clinicians should consider nitrofurantoin as a reasonable alternative to TMP-SMX and fluoroquinolones for first-line therapy for uncomplicated UTIs. To analyze the costs of nitrofurantoin use compared to those of other antibiotics recommended for treatment of uncomplicated urinary tract infection (UTI). We used a decision analysis model to perform cost-minimization and sensitivity analyses to determine the level of trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinolone resistance that would favor the use of nitrofurantoin as a first-line empirical treatment of uncomplicated UTIs. The model used a program perspective to evaluate costs. Nitrofurantoin was cost-minimizing when the prevalence of fluoroquinolone resistance exceeded 12% among uropathogens or the prevalence of TMP-SMX resistance exceeded 17%. On 2-way sensitivity analysis, variables that had a significant impact on our cost-minimization threshold included cost of antibiotics and probability of clinical cure with antibiotics. From a payer perspective, nitrofurantoin appears to be a reasonable alternative to TMP-SMX and fluoroquinolones for empirical treatment of uncomplicated UTIs, especially given the current prevalence of antibiotic resistance among community uropathogens. On the basis of efficacy, cost, and low impact on promoting antimicrobial resistance, clinicians should consider nitrofurantoin as a reasonable alternative to TMP-SMX and fluoroquinolones for first-line therapy for uncomplicated UTIs." @default.
• W2055794120 created "2016-06-24" @default.
• W2055794120 creator A5016777889 @default.
• W2055794120 creator A5033298339 @default.
• W2055794120 creator A5045853689 @default.
• W2055794120 creator A5052781570 @default.
• W2055794120 date "2011-06-01" @default.
• W2055794120 modified "2023-10-15" @default.
• W2055794120 title "Nitrofurantoin Compares Favorably to Recommended Agents as Empirical Treatment of Uncomplicated Urinary Tract Infections in a Decision and Cost Analysis" @default.
• W2055794120 cites W1971112262 @default.
• W2055794120 cites W1989051873 @default.
• W2055794120 cites W1993339885 @default.
• W2055794120 cites W1995013130 @default.
• W2055794120 cites W1996128305 @default.
• W2055794120 cites W2017210944 @default.
• W2055794120 cites W2022474883 @default.
• W2055794120 cites W2026146874 @default.
• W2055794120 cites W2031602862 @default.
• W2055794120 cites W2036352102 @default.
• W2055794120 cites W2037554663 @default.
• W2055794120 cites W2037753522 @default.
• W2055794120 cites W2039330653 @default.
• W2055794120 cites W2043231579 @default.
• W2055794120 cites W2051879580 @default.
• W2055794120 cites W2058162439 @default.
• W2055794120 cites W2071333299 @default.
• W2055794120 cites W2079738891 @default.
• W2055794120 cites W2083317144 @default.
• W2055794120 cites W2083421585 @default.
• W2055794120 cites W2106311471 @default.
• W2055794120 cites W2113206822 @default.
• W2055794120 cites W2113664107 @default.
• W2055794120 cites W2114934318 @default.
• W2055794120 cites W2120644678 @default.
• W2055794120 cites W2120750073 @default.
• W2055794120 cites W2120866334 @default.
• W2055794120 cites W2140799056 @default.
• W2055794120 cites W2141328216 @default.
• W2055794120 cites W2142909774 @default.
• W2055794120 cites W2150560870 @default.
• W2055794120 cites W2150880937 @default.
• W2055794120 cites W2154995538 @default.
• W2055794120 cites W2160334804 @default.
• W2055794120 cites W2161630897 @default.
• W2055794120 cites W2163820951 @default.
• W2055794120 cites W2164980718 @default.
• W2055794120 cites W2167201002 @default.
• W2055794120 cites W2414425905 @default.
• W2055794120 cites W26774890 @default.
• W2055794120 cites W4229984702 @default.
• W2055794120 cites W4245920351 @default.
• W2055794120 cites W4375840003 @default.
• W2055794120 doi "https://doi.org/10.4065/mcp.2010.0800" @default.
• W2055794120 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3104907" @default.
• W2055794120 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21576512" @default.
• W2055794120 hasPublicationYear "2011" @default.
• W2055794120 type Work @default.
• W2055794120 sameAs 2055794120 @default.
• W2055794120 citedByCount "66" @default.
• W2055794120 countsByYear W20557941202012 @default.
• W2055794120 countsByYear W20557941202013 @default.
• W2055794120 countsByYear W20557941202014 @default.
• W2055794120 countsByYear W20557941202015 @default.
• W2055794120 countsByYear W20557941202016 @default.
• W2055794120 countsByYear W20557941202017 @default.
• W2055794120 countsByYear W20557941202018 @default.
• W2055794120 countsByYear W20557941202019 @default.
• W2055794120 countsByYear W20557941202020 @default.
• W2055794120 countsByYear W20557941202021 @default.
• W2055794120 countsByYear W20557941202022 @default.
• W2055794120 countsByYear W20557941202023 @default.
• W2055794120 crossrefType "journal-article" @default.
• W2055794120 hasAuthorship W2055794120A5016777889 @default.
• W2055794120 hasAuthorship W2055794120A5033298339 @default.
• W2055794120 hasAuthorship W2055794120A5045853689 @default.
• W2055794120 hasAuthorship W2055794120A5052781570 @default.
• W2055794120 hasBestOaLocation W20557941202 @default.
• W2055794120 hasConcept C126322002 @default.
• W2055794120 hasConcept C177713679 @default.
• W2055794120 hasConcept C2777629877 @default.
• W2055794120 hasConcept C2779425571 @default.
• W2055794120 hasConcept C2780728791 @default.
• W2055794120 hasConcept C2781072439 @default.
• W2055794120 hasConcept C501593827 @default.
• W2055794120 hasConcept C71924100 @default.
• W2055794120 hasConcept C77411442 @default.
• W2055794120 hasConcept C86803240 @default.
• W2055794120 hasConcept C89423630 @default.
• W2055794120 hasConcept C94665300 @default.
• W2055794120 hasConceptScore W2055794120C126322002 @default.
• W2055794120 hasConceptScore W2055794120C177713679 @default.
• W2055794120 hasConceptScore W2055794120C2777629877 @default.
• W2055794120 hasConceptScore W2055794120C2779425571 @default.
• W2055794120 hasConceptScore W2055794120C2780728791 @default.
• W2055794120 hasConceptScore W2055794120C2781072439 @default.
• W2055794120 hasConceptScore W2055794120C501593827 @default.
• W2055794120 hasConceptScore W2055794120C71924100 @default.
• W2055794120 hasConceptScore W2055794120C77411442 @default.

• next